AOL Money & Finance

Pharmacy benefits management benefit CVS (CVS)

More

"Regardless of how you analyze the company, CVS Caremark (NYSE: CVS) stands out," says Chuck Carlson.

In The DRIP Investor, he explains, "Our Quadrix stock-rating system ranks more than 4,000 stocks based on more than 100 different variables. CVS scores better than 90% of the stocks in the Quadrix universe."

"CVS's Sector score -- that is, a score devised by evaluating the metrics that have the most influence over performance in that particular sector -- is also impressive at 95 out of a possible 100.

"The good news is that investors can buy this stock at what appears to be an attractive valuation at just 11 times the 2010 consensus earnings of $3 per share.

"Although healthcare-related stocks have been affected by uncertainties surrounding health-care reform, CVS stands to be one of the winners should more people obtain insurance coverage. The stock represents a quality buy at current levels.

"CVS operates two segments. Retail drugstores generated 53% of sales in 2008, while pharmacy-benefit management (PBM) accounted for the rest.

"Prescription drugs account for about two-thirds of retail sales, with the balance coming from general merchandise (15%), over-the-counter drugs and personal care (13%), and beauty/cosmetics (4%).

"The PBM unit contracts with employers, insurance companies, and other sponsors of health-benefit plans to administer drug coverage for groups.

"Typically, a PBM will buy drugs in bulk at a discount and pass on some of the savings to patients in its benefit plans. Caremark entered the PBM business via its $26.5 billion acquisition of Caremark in 2007.

"Melding a PBM operation with a drugstore chain provides opportunities for cross-marketing services. CVS should be one of the few companies posting higher per share profits in 2009.

"The consensus estimate for 2009 is $2.60, up from $2.44 per share in 2008. That estimate could prove conservative, as CVS has beaten the consensus earnings estimate in each of the last two quarters.

"CVS trades at a PE ratio that is on the low side relative to its historical range. Profit growth should accelerate in 2010, and long-term growth prospects are excellent. The stock, down sharply from its 2008 high of more than $44 per share, represents one of the better buys in the market.

"DRIP investors take note that CVS offers a direct-purchase plan whereby any investor may buy the first share and every share directly from the company."

Steven Halpern's TheStockAdvisors.com offers a free daily overview of the favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.

Reader Comments (Page 1 of 1)

Symbol Lookup
IndexesChangePrice
DJIA-17.2410,433.71
NASDAQ-6.832,169.18
S&P 500-0.591,105.65

Last updated: November 25, 2009: 12:52 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines